logo
logo

ILIAS Biologics Closes $20.6 Million Series B Financing

ILIAS Biologics Closes $20.6 Million Series B Financing

09/28/20, 11:18 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/KR.svgdaejeon
Money raised
$20 million
Round Type
series b
ILIAS Biologics Inc. (the "Company" or "ILIAS"), a leading exosome-based therapeutics company, announced today that the Company has completed a Series B financing round of $20.6 million in South Korea.

Company Info

Company
Ilias Biologics Inc.
Location
daejeon, daejeon, south korea
Additional Info
ILIAS Biologics Inc. (previously Cellex Life Sciences, Inc.) was established in 2015 in South Korea to develop exosome-based therapeutics. ILIAS is currently developing various pipelines including inflammatory diseases and oncology. To learn more about ILIAS Biologics Inc, visit the website at www.iliasbio.com.